Research Antibodies

 
News Articles for Research Antibodies top ^
2014/3/17
Amorfix and Trellis Bioscience to collaborate on anti-CD38 antibody treatment for cancer Canada NewsWire TSX: AMF TORONTO , March 17, 2014 /CNW/ - Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced that it has entered into a collaboration with Trellis Bioscience to develop antibodies against misfolded CD38 protein as a treatment for haematological malignancies including leukemia and lymphoma.
Sign-up for Amorfix and Trellis Bioscience to collaborate on anti-CD38 antibody treatment for cancer investment picks
2014/3/31
SAN FRANCISCO and WALTHAM, Mass.
Sign-up for Kindred Bio and X-Body Announce an Exclusive Collaboration for Discovery of Antibodies for Companion Animal Health investment picks
2014/1/13
Agenus Inc. (NASDAQ: AGEN), a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced that it has entered into a definitive agreement to acquire 4-Antibody AG, a private European-based biopharmaceutical company.
Sign-up for Agenus Enters into Definitive Agreement to Acquire Privately Held 4-Antibody AG investment picks
2014/4/3
HAMPTON, N.J., April 3, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that data from preclinical studies evaluating the anti-tumor activity of the antibody-drug conjugate (ADC) CDX-014 will be presented at the American Association of Cancer Research (AACR) Annual Meeting 2014 in San Diego, California, April 5-9.
Sign-up for Celldex Therapeutics to Present Antibody-Drug Conjugate CDX-014 Preclinical Proof of Concept Data at AACR 2014 investment picks
2013/11/11
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that multiple abstracts will be presented at the 55 th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in New Orleans, Louisiana, December 7-10, 2013, highlighting the following: “The presentations at ASH demonstrate the breadth of our development program for ADCETRIS in CD30-positive malignancies, including frontline and relapsed patients and disease areas ranging from Hodgkin lymphoma to mature T-cell lymphoma and diffuse large B-cell lymphoma,” said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development at Seattle Genetics.
Sign-up for Seattle Genetics to Present Clinical Data from Broad ADCETRIS® (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugate (ADC) SGN-CD19A at ASH 2013 investment picks
2014/2/13
Agenus Inc. (Nasdaq: AGEN), a biopharmaceutical company developing novel immunotherapeutics, including a portfolio of checkpoint modulators (CPMs), anti-cancer vaccines and adjuvants, today completed the previously announced acquisition of 4-Antibody AG, a private European-based biopharmaceutical company.
Sign-up for Agenus Completes Acquisition of 4-Antibody investment picks
2014/3/13
SAN DIEGO , March 13, 2014 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced a strategic immuno-oncology collaboration with TESARO, Inc. (NASDAQ: TSRO) , an oncology-focused biopharmaceutical company.
Sign-up for AnaptysBio And TESARO Announce Strategic Immuno-Oncology Antibody Collaboration investment picks
2014/3/31
MORRIS PLAINS, N.J., March 31, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) , a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that four posters will be presented at the 2014 Annual Meeting of the American Association for Cancer Research to be held in San Diego, CA, from April 5 – 9, 2014.
Sign-up for Immunomedics to Provide Clinical Trial Updates on Solid-Tumor Antibody-Drug Conjugates at Cancer Conference investment picks
2013/7/16
MORRIS PLAINS, N.J., July 16, 2013 (GLOBE NEWSWIRE) -- Immunomedics , Inc. (Nasdaq:IMMU) ,a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported the issuance of U.S. Patent 8,486,395 with expiration on August 2, 2024.
Sign-up for Immunomedics Constructs New Humanized Antibody for B-Cell Mediated Cancer and Autoimmune Diseases investment picks
2013/9/10
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers have presented preliminary data from a single-arm Phase 2 study of eculizumab (Soliris ® ) as an investigational therapy to prevent acute antibody-mediated rejection (AMR) in sensitized deceased-donor kidney transplant recipients.
Sign-up for Study Evaluating Eculizumab (Soliris®) in Preventing Antibody-Mediated Rejection (AMR) in Kidney Transplant Recipients Presented at the European Society for Organ Transplantation (ESOT) Annual Congress investment picks
Breakthrough Inovio DNA Technology Application Successfully Demonstrates Monoclonal Antibody Generation BLUE BELL, Pa.
Sign-up for Inovio Pharmaceuticals Targets Transformation of Monoclonal Antibody Therapies investment picks
http://media.marketwire.com/attachments/201009/639319_logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1066698&ProfileId=051205&sourceType=1 TUSTIN, CA --
Sign-up for Data Presentation at Society for Immunotherapy of Cancer Annual Meeting Supports Potential of Peregrine Pharmaceuticals' Novel Immunotherapy Bavituximab in Combination With Anti-CTLA-4 Antibodies investment picks
2013/11/14
Deal bolsters Sorrento's G-MAB® antibody library with Concortis Biosystems' proprietary conjugation chemistries and toxins for powerful ADC platform SAN DIEGO , Nov.
Sign-up for Sorrento Enters into Definitive Agreement to Acquire Antibody Drug Conjugation Technology investment picks
2013/12/7
Seattle Genetics, Inc. (Nasdaq: SGEN) today presented interim phase 1 clinical data from SGN-CD19A, an antibody-drug conjugate (ADC) in development for the treatment of B-cell malignancies, including acute lymphoblastic leukemia (ALL), at the 55 th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in New Orleans, Louisiana, December 7-10, 2013.
Sign-up for Seattle Genetics Presents Data from Novel Antibody-Drug Conjugate (ADC) SGN-CD19A at ASH 2013 investment picks
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has further expanded its antibody-drug conjugate (ADC) collaboration with AbbVie (NYSE: ABBV). Under the expanded deal, AbbVie will pay an upfront fee of $25 million for additional rights to utilize Seattle Genetics’ ADC technology with AbbVie antibodies against oncology targets, including access to Seattle Genetics’ pyrrolobenzodiazepine (PBD) dimer ADC technology and EC-mAb site-specific conjugation technology.
Sign-up for Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie investment picks
2014/4/8
-- Preclinical Studies Presented at 2014 Annual Meeting of the American Association for Cancer Research (AACR) -- SAN DIEGO, April 8, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) , a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported results from preclinical studies on the Company's two investigational SN-38-containing antibody drug conjugates (ADCs), IMMU-130 and IMMU-132, that demonstrated a high therapeutic index for both agents.
Sign-up for Immunomedics Reports Preclinical Results on SN-38 Antibody-Drug Conjugates as a Potential Novel Platform for Treating Cancer investment picks
2013/8/14
http://media.marketwire.com/attachments/201009/639319_logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1042886&ProfileId=051205&sourceType=1 TUSTIN, CA --
Sign-up for Bavituximab's Mechanism of Action Highlighted at Immunomodulatory Therapeutic Antibodies for Cancer Conference investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Research Antibodies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Research Analysts  |  Next: Research Applications